<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953053</url>
  </required_header>
  <id_info>
    <org_study_id>FL5940-0001-CN</org_study_id>
    <nct_id>NCT03953053</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of FLACS With the FEMTO LDV Z8 Laser Compared to Conventional Cataract Surgery in Chinese Patients</brief_title>
  <acronym>Z8CAT01</acronym>
  <official_title>Safety and Efficacy of FLACS With the FEMTO LDV Z8 Laser Compared to Conventional Cataract Surgery in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziemer Ophthalmic Systems AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziemer Ophthalmic Systems AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be designed as a multi-center randomized non-inferiority clinical trial to&#xD;
      demonstrate safety and efficacy of the FEMTO LDV Z8 laser for cataract surgery in a Chinese&#xD;
      population in China compared to the conventional technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this three center, prospective, interventional, randomized controlled study we aim to&#xD;
      determine safety and efficacy of the FEMTO LDV Z8 laser as compared to conventional technique&#xD;
      in Chinese patients diagnosed with cataract of any severity grade that are eligible to&#xD;
      undergo cataract surgery with age 50 years and a maximum age of 80 years in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial cell loss</measure>
    <time_frame>4 month</time_frame>
    <description>To determine whether the FLACS with the FEMTO LDV Z8 laser is non-inferior to measured using the NSP 9900, KONAN MEDICAL, and calculated according to: postoperative endothelial cell loss = preoperative endothelial count - postoperative endothelial cell count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra- and post- surgical complications</measure>
    <time_frame>4 month</time_frame>
    <description>Diagnosis of Complications in combination with usual follow-up measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dissipated energy (CDE)</measure>
    <time_frame>4 month</time_frame>
    <description>Recording of CDE on Phaco device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound (US) total time</measure>
    <time_frame>4 month</time_frame>
    <description>Record of US Energy applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated fluid usage (EFU)</measure>
    <time_frame>4 month</time_frame>
    <description>Record of EFU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness (CCT)</measure>
    <time_frame>4 month</time_frame>
    <description>Mesurement of the Central Corneal Thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity (UDVA)</measure>
    <time_frame>4 month</time_frame>
    <description>Measurement of UDVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected distance visual acuity (CDVA)</measure>
    <time_frame>4 month</time_frame>
    <description>Measurement of CDVA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>FLACS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gold Standard Method with manual rhexis with pinzette and phaco emulsification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Femtosecond Laser Assissted Cataract Surgery</intervention_name>
    <description>During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body</description>
    <arm_group_label>FLACS Group</arm_group_label>
    <arm_group_label>Manual Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible to undergo cataract extraction by phacoemulsification with primary&#xD;
             intraocular lens implantation&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Male or female, between 50 and 80 years of age (50 and 80 are included).&#xD;
&#xD;
          -  IOL chosen for implantation a monofocal aspheric IOL of 6mm optic diameter&#xD;
&#xD;
          -  Willing to comply with all study procedures and able to return for scheduled follow-up&#xD;
             examinations&#xD;
&#xD;
          -  Willing to adhere to the medication (to prevent inflammation and infection) regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal disease or pathology, such as corneal scaring or opacity, that precludes&#xD;
             transmission of laser wavelength or that distorts laser light&#xD;
&#xD;
          -  Poorly dilating pupil or other defect of the pupil that prevents the iris from&#xD;
             adequate retraction peripherally (e.g., intraoperative floppy iris syndrome)&#xD;
&#xD;
          -  Glaucoma or ocular hypertension, pseudoexfoliation&#xD;
&#xD;
          -  Corneal endothelial pathology where endothelial cell count is compromised (Fuchs&#xD;
             endothelial dystrophy and others)&#xD;
&#xD;
          -  Complicated cataract, such as traumatic, white, intumescent or posterior and anterior&#xD;
             subcapsular cataracts&#xD;
&#xD;
          -  Nystagmus or hemofacial spasm preventing placement of the patient interface&#xD;
&#xD;
          -  Previous intraocular or corneal surgery of any kind, including any type of surgery for&#xD;
             either refractive or therapeutic purposes in either eye&#xD;
&#xD;
          -  Allergy to medications required in surgery, pre- and post-operative treatment&#xD;
&#xD;
          -  History of lens or zonular instability&#xD;
&#xD;
          -  Keratoconus or keratectasia&#xD;
&#xD;
          -  Immune compromised or diagnosis of ophthalmic disease: ocular herpes zoster or&#xD;
             simplex, lupus, collagenosis and other acute or chronic illnesses that increases the&#xD;
             risk to the subject or confounds the outcomes of this study in the opinion of the&#xD;
             study PI (Principal Investigator)&#xD;
&#xD;
          -  Anterior chamber depth (ACD) &lt; 1.5 mm or &gt; 4.8 mm as measured from the corneal&#xD;
             endothelium.&#xD;
&#xD;
          -  Developmental disability or cognitive impairment that would make informed consent and&#xD;
             the assessment of visual acuity impossible&#xD;
&#xD;
          -  Concurrent participation in another ophthalmological clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A-Yong Yu, MD PHD Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziemer Ophthalmic Systems AG</name>
      <address>
        <city>Port</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femto Cataract Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

